Compare companies
| Sight Sciences, Inc. | Gilead Sciences | Amgen | ||||
|---|---|---|---|---|---|---|
| Capitalization | ||||||
| Price | 2.69 | 107.89 | 306.86 | |||
| Price priv. | ||||||
| Number of shares, million | 48.63 | 1258 | 538 | |||
| Capitalization, billion | 0.3552 | 94.55 | 140.05 | |||
| EBITDA, billion | -0.0567 | 7.61 | 7.9 | |||
| EV, billion | 0.157 | 119.11 | 206.55 | |||
| Profit and loss report | ||||||
| Net profit, billion | -0.0555 | 5.67 | 6.72 | |||
| Revenue, billion | 0.0811 | 27.12 | 28.19 | |||
| EPS | -1.14 | 4.5 | 12.49 | |||
| Balance | ||||||
| Assets, billion | 0.1667 | 62.13 | 97.15 | |||
| Debt, billion | 0.0345 | 24.99 | 64.61 | |||
| Balance cost, billion | 0.1202 | 22.75 | 6.23 | |||
| Cash, billion | 0.1381 | 6.09 | 10.94 | |||
| Coefficients | ||||||
| Dividend yield, % | 0 | 3.69 | 2.92 | |||
| Dividend | 0 | 3.87 | 9.13 | |||
| Dividend yield priv., % | 0 | 0 | 0 | |||
| Dividend priv. | 0 | 0 | 0 | |||
| Dividends/profit, % | 0 | 67.24 | 67.83 | |||
| P/S | 3.2 | 3.7 | 5.42 | |||
| P/BV | 2.16 | 4.41 | 24.53 | |||
| P/E | 0 | 17.69 | 22.76 | |||
| Ev/Ebitda | -2.77 | 15.66 | 26.16 | |||
| Debt/Ebitda | -0.6089 | 3.29 | 8.18 | |||
| Efficiency | ||||||
| ROE | -46.21 | 24.9 | 107.78 | |||
| ROA | -33.33 | 9.12 | 6.91 | |||
| ROIC | -80.28 | 11.06 | 17 | |||
| Ebitda margin | -69.9 | 28.05 | 28.01 | |||
| Net margin | -68.53 | 20.89 | 23.83 | |||
| Momentum | ||||||
| 1 week, price changes | -9.01 % | +0.3535 % | -2.82 % | |||
| 1 month, price changes | +7.43 % | -2.83 % | -0.9234 % | |||
| 3 months, price changes | -25.9 % | +14.84 % | +16.02 % | |||
| 6 months, price changes | -58.91 % | +29.93 % | -3.84 % | |||
| 1 year, price changes | -49.34 % | +47.77 % | +7.18 % | |||
| 3 years, price changes | -67.18 % | +81.82 % | +31.59 % | |||
| 5 years, price changes | +80.42 % | +33.46 % | ||||
| 10 years, price changes | +24.66 % | +101.52 % | ||||
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
